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A mathematical model of combined 
CD8 T cell costimulation by 
4-1BB (CD137) and OX40 (CD134) 
receptors
Anna Konstorum  1, Anthony T. Vella2, Adam J. Adler2 & Reinhard C. Laubenbacher1,3
Combined agonist stimulation of the TNFR costimulatory receptors 4-1BB (CD137) and OX40(CD134) 
has been shown to generate supereffector CD8 T cells that clonally expand to greater levels, survive 
longer, and produce a greater quantity of cytokines compared to T cells stimulated with an agonist of 
either costimulatory receptor individually. In order to understand the mechanisms for this effect, we 
have created a mathematical model for the activation of the CD8 T cell intracellular signaling network 
by mono- or dual-costimulation. We show that supereffector status is generated via downstream 
interacting pathways that are activated upon engagement of both receptors, and in silico simulations 
of the model are supported by published experimental results. The model can thus be used to identify 
critical molecular targets of T cell dual-costimulation in the context of cancer immunotherapy.
It is now well-understood that T lymphocytes respond not only to antigens derived from infectious agents, but 
also to (tumor-specific and tumor-associated) antigens1. An improper response by T cells can result in infection 
or tumor growth (if T cells are not properly activated) or autoimmune disease (if the T cells treat healthy host 
cells as infected)2,3.
T cell receptors are transmembrane receptors that play a critical role in modifying the T cell response 
after innate immune cells have presented antigen to the T Cell Receptor (TCR). Activation of CD28, the most 
well-known costimulatory receptor4, results in T cell proliferation, cytokine production, and other pro-effector 
phenotypic traits. Other costimulatory receptors include OX40 (CD134), 4-1BB (CD137), and CD275. T cells 
also express checkpoint inhibitory receptors, which are necessary to prevent auto-immune disorders, the most 
well-studied of which are CTLA-4 and PD-1 due to their over-activation by certain tumors6. These receptors 
inhibit overlapping pathways, not all of which have been identified experimentally7. Predicting the phenotypic 
outcome of combinatorial costimulatory receptor activation is not currently possible but highly desired, especially 
in the context of drug development for cancer immunotherapy. For example, pharmacological agonist antibod-
ies against OX40 and 4-1BB T cell costimulatory receptors have been found to be effective individually8,9 in 
improving systemic immune response and reducing tumor burden. Additionally, their effect when given in com-
bination (termed dual costimulation) is cooperative in mitigating tumor growth10–12 and shows synergism with 
respect to CD8 T cell effector status13,14. Indeed, a combination therapy targeting both receptors in the context 
of several cancers is currently in clinical trials15. Nevertheless, the molecular mechanisms by which the effect of 
dual costimulation occurs have not been completely elucidated. Both 4-1BB and OX40 costimulatory receptors 
belong to the Tumor Necrosis Factor Receptor (TNFR) family, and act by binding to TNF receptor-associated 
factor (TRAF)-acting proteins, but they bind a different subset of TRAFs16, signal through overlapping5,16, and 
non-overlapping17 pathways, and preferentially activate different subsets of lymphocytes5. Therefore, their dual 
action in generating supereffector T cells may occur at either the intracellular, network-level scale via optimized 
network activation, at the population-scale via activation of the major subsets of T cells, or both.
Cancer immunotherapy refers to development of drugs to stimulate the immune system to fight the tumor and 
is a highly active area in basic and clinical cancer therapeutics research18. Since the effect of combining various 
immunotherapy drugs is difficult to predict, mathematical models of T-cell modulation by costimulatory receptor 
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activity can help scientific researchers to build a more complete understanding of this process, and thereby design 
optimal combination therapies of immunotherapy drugs19.
While there has been a strong modeling effort to determine TCR specificity with respect to antigen binding 
(e.g.20–22 and see23 for review), modeling of downstream signaling pathways of the TCR and costimulatory recep-
tors has been more sparse. Saez-Rodriguez et al.24 developed and partially validated a comprehensive Boolean 
network model of TCR and CD28 activation in CD4 and CD8 T cells, which was later extended by Beyer et al.25 to 
include an IL-2 receptor signaling module. Saadatpour et al.26 also developed a dynamic Boolean model for CD8 
signaling in the context of T cell large granular lymphocyte (T-LGL) leukemia. The models all provided insight 
into dynamics of specific downstream pathways in T cell signaling, but did not include the TNFR family receptors 
4-1BB or OX40 or their downstream components.
Results
Model for intracellular activation of CD8 T cells by OX40 and 4-1BB receptor agonists. We 
present a model of intracellular CD8 T cell activation by OX40 and 4-1BB agonists using a stochastic multistate 
discrete logic framework to represent key molecules involved in the downstream signaling pathways of OX40 
and/or 4-1BB, as summarized in Fig. 1. This framework allows for the representation of qualitative relationships 
between variables and requires much fewer parameters and kinetic information to develop than continuous mod-
els. Logic-based models have been used to investigate and elucidate a variety of signaling networks27,28. In such 
a system, state transitions can be represented using transition tables, where all possible combinations of input 
values for contributing variables are assigned an output state for a given species. A probability update function is 
assigned for each update rule (which is specified by a transition table) in order to more realistically represent the 
biological scenario where not all possible interactions may occur at each time step. Derivation of the transition 
tables for the modeled species, as well as the simulation methods, are described in the Methods. A more detailed 
discussion of the mechanics of the discrete model can be found in the Supplementary Materials.
Since the data that we use for development of the model comes from a variety of literature sources, many of 
which are qualitative in nature, we make a number of simplifying assumptions in order to reduce the parameter 
burden. First, we focus our goal with respect to the model such that it can be used to explain the synergy of 4-1BB 
and OX40 activation. The model components were chosen based on primary literature in the field of downstream 
signaling for 4-1BB and/or OX40 that contained appropriate information to build the dynamic interactions for 
the model. Development of the transition tables was based on literature-derived specific pathway interactions 
(such as ligation of OX40 that leads to subsequent activation to TRAF529 or inhibition of survival by Bim30). 
Outcomes of mono- or dual-costimulation on survival, cytokine release, or activation of any particular molec-
ular species were determined by the cumulative effect of multiple interacting pathway components, which were 
simulated by the model. References utilized during the model development phase are distinct from validation 
references.
Further, we assume optimal TCR activation, as many studies that we use to develop and validate our model 
use a vaccine strategy to ensure a large bolus of TCR triggering. Indeed, TCR activation is required for 4-1BB 
and OX40 upregulation, and thus is assumed to occur in all simulations of the model. We also consider that 
while knocked-down or overexpressed signaling components will continue to fluctuate in in vitro or in vivo set-
tings, these fluctuations will be of an order lower than under normal conditions, hence due to the coarse-grained 
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Figure 1. A model for T cell costimulation by the agonists of 4-1BB and OX40. TRAF proteins, which are 
activated by 4-1BB and OX40, are labeled in yellow, their downstream effectors, Bim, JNK, and NF-κB are in 
blue, and the phenotypic outcomes: cellular survival and cytokine production, are in pink. Stimulation of T cells 
via their TCR receptor is assumed for the course of the simulation. Shown is stimulation of 4-1BB and OX40 via 
their natural ligands, activation via antibodies can also take place.
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nature of our model, we take perturbed values of these signaling components to be constant (‘high’ or’low’, for 
overexpression or knock-out, respectively) during the course of the simulation. Further, we note that while OX40 
is considered to be more active in CD4 (T helper) cells, and 4-1BB in CD8 (cytotoxic) T cells31, OX40 activity 
has been found to be important for activated CD8 T cell survival, proliferation, and cytokine production (even 
independently of CD4 T cell involvement)32,33, therefore we model the action of both receptors on CD8 T cells. 
Additionally, expression of OX40 and 4-1BB peaks at approximately 48 hours after antigen presentation to naive 
T cells5. Coexpression of the receptors is likely to continue for approximately 2–4 days post-activation34,35 which 
represents a critical phase of effector T cell differentiation, and is thus clinically important for development of 
sufficient numbers of these antigen-specific cytotoxic T cells36. Thus, focusing the modeling effort on this time 
period represents an efficient effort to understand and simulate a critical phase of T cell differentiation during 
which OX40 and 4-1BB play an important role in the quality of T cell effector generation. We take the expres-
sion and activation of the coreceptors to be constant during this peak period. More generally, our model may be 
considered to represent the relevant time period during which therapeutic response is elicited from mono- or 
dual-costimulation, and this period may be extended if the therapy is administered multiple times over longer 
periods12,37. Finally, OX40 and 4-1BB can be activated endogenously by their respective ligands OX40L and 
4-1BBL, which are expressed on activated APCs such as DCs, B cells, and macrophages, or exogenously by mon-
oclonal agonist antibodies38. While our model does not distinguish endogenous or exogenous activation of the 
receptors, it can serve as a framework for developing the distinction if desired. We assume baseline production 
and decay rates of approximately the same order for the variables, hence we do not include either in the model.
Dual costimulation in the baseline model. By varying 4-1BB (I) and OX40 (Ox) we consider behavior 
of the model under conditions of no costimulation (I = Ox = low), mono-costimulation (I = low and Ox = high 
or I = high and Ox = low), and dual-costimulation (I = Ox = high) (Fig. 2). We observe that under conditions of 
no costimulation, the TRAF proteins are not activated, and hence NF-κB (Nk) is at its lowest level, and Bim at its 
highest. JNK maintains an intermediate level since, while it is not being activated by TRAF2 (Tr2), it is also not 
being inhibited by Nk. Bim is at a low level due to lack of Ox. Survival (S), since it is an outcome of the balance 
between activators Nk and PKB and inhibitors Bim and JNK, is at its lowest level (Fig. 2a). Cytokine release (C) is 
similarly low due to the absence of Nk (a moderate level of JNK with a low level of Nk is not sufficient to raise C 
levels to moderate).
Upon mono-costimulation with I (Fig. 2b), S increases to a moderate level due to a moderate increase in Nk 
(an outcome of higher Tr2 and a I-mediated decrease in Bim). Cytokine production shows a similarly modest 
Figure 2. Behavior of each species during conditions of (a) no costimulation, (b) 4-1BB mono-costimulation, 
(c) OX40 mono-costimulation, and (d) dual costimulation. Low, medium, and high activity of molecular species 
are represented by Levels 0, 1, and 2, respectively. The solid line and shaded region represent, respectively, the 
mean and standard deviation of 100 simulations.
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increase due to the increase in Nk. The model thus predicts that upon mono-costimulation with one agonist, 
CD8 T cells will increase cytokine production and survival to a moderate extent. These results are consistent 
with experimentally observed results of increased survival and cytokine production in CD8 T cells from healthy 
donors39 and melanoma tumor-infilatrating CD8 lymphocytes40 when exposed to 4-1BB costimulatory ligand or 
agonist. Survival also increases to a moderate level upon mono-costimulation with Ox (Fig. 2c), this time due to 
an increase in PKB, alongside with an increase in Nk, and a moderate decrease in Bim. Cytokine production is 
increased to a moderate level due to the increase in Nk. Increased CD8 T cell survival and cytokine production 
have been been found to be increased upon costimulation by an OX40 agonist in an adoptive-trasferred OT-I 
CD8 T cell model32,41.
Dual costimulation results in the highest survival level due to high NK and PKB activity, and low Bim activ-
ity (Fig. 2d). Therefore, the model predicts that multiple pathways converge to maximize survival in the dual 
costimulation system. The strong increase in survival and cytokine production in dual-costimulated cells over 
mono-costimulated cells was observed in Lee et al.13 using an OT-I T cell transfer model. The group found that 
mono- and dual-costimulated CD8 T cells were accumulating to different extents - with greater accumulation 
by dual-costimulated cells (Fig. 4b13). Thus, the group found that the more profound CD8 T cell clonal expan-
sion elicited by dual- compared to mono-costimulation during in vivo immunization (Fig. 4b13) could not be 
explained by enhanced proliferation. More specifically, when two complimentary flow cytometry-based methods 
were used to measure CD8 T cell proliferation (dilution of the fluorescent tracking dye CFSE, and incorporation 
of the deoxynucleotide analogue BrdU into replicating DNA), no differences were observed between dual- and 
mono-costimulation treatments at either the early, middle or late phases of the proliferative response (spanning 
from 0 to 105 hours, Fig. 4a,c,d13). Taken together, these results indicated that the effect of dual-costimulation 
in augmenting CD8 T cell clonal expansion, compared to either mono-costimulation, was due to its ability to 
program enhanced survival. Moreover, the group found that neither clonal expansion nor cytokine production 
was dependent on CD4 help (Fig. 613), highlighting the criticality of intracellular cascades mediated by OX40 and 
4-1BB in CD8 T cell supereffector generation.
Effect of knockout on the effectiveness of dual-costimulation. Lee et al.42 cultured OT-I CD8 T 
cells that had been adoptively transferred into C57BL/6 mice, immunized with antigen and dual-costimulated 
with OX40 and 4-1BB, and subsequently purified from spleen, with a number of inhibitors to signaling cascades 
including PD98059 and U0126 (inhibitors of upstream regulators of ERK), Wortmannin and LY294002 (inhibi-
tors of PI-3K, which is necessary for PKB stimulation), SP500125 (a JNK inhibitor), and Bay11 (an NF-κB inhib-
itor). The group found that only Bay11 blocked the dual-costimulation-induced cell survival of the OT-I CD8 T 
Figure 3. Simulating knock-out experiments of (a) ERK, (b) PKB, (c) JNK, and (d) Nk for dual-costimulated 
cells. The solid line and shaded region represent, respectively, the mean and standard deviation of 100 
simulations.
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cells. We thus decided to simulate this set of experiments by knocking-out ERK, PKB, JNK, or Nk (Fig. 3). The 
model predicts that only Nk knock-out results in a decrease in cell survival, similar to the observations by Lee et 
al.42. Our model can help to explain why only the NF-κB inhibitor is capable of reducing dual-costimulated T cell 
survival: the remainder of the species can compensate for ERK, PKB, or JNK knockouts in dual-costimulated cells 
so that survival is not impacted, but Nk knock-out not only removes Nk from promoting survival, but also from 
acting on JNK (and thereby Bim) to minimize their antaganostic impact on survival. Only PKB is not affected, but 
it cannot completely compensate for the loss of Nk, and gain in JNK and Bim.
Cellular phenotype as predictor of response to mono- and dual-costimulation. A major chal-
lenge in cancer immunotherapy (and, cancer therapy in general) is predicting the responsiveness of the patient 
to a particular immunotherapeutic treatment43,44. With the advent of tumor single-cell sequencing methods45,46, 
it may be possible to predict responsiveness to therapy based on the transcriptomic profiles of tumor and 
tumor-resident cells, a fraction of which are CD8 T cells. We consider this challenge by asking whether a CD8 T 
cell with perturbation in one of the four major downstream pathways of 4-1BB (I) and/or OX40 (Ox) (ERK, JNK, 
PKB, or NK) would be more or less responsive to mono- or dual-costimulation treatment (Fig. 4). The subsequent 
results represent predictions beyond what is currently studied in the experimental literature, but provide testable 
predictions for future experimental investigation.
While the model predicts that only Nk knock-out will abrogate the dual-costimulation response, further 
predictions include that ERK knock-out and JNK overexpression will abrogate survival mono-costimulation 
responses to both agonists, and PKB knock-out will abrogate the survival response to Ox while Nk knockout 
will abrogate survival response to I and cytokine response to Ox. Interestingly, PKB overexpression is predicted 
to result in maximal survival independent of treatment, but cytokine response will still depend on treatment, 
whereas JNK overexpression will lower survival responsiveness while increasing cytokine expression in response 
to stimulation in comparison to wild-type cells. Unsurprisingly, Nk overexpression is predicted to yield the high-
est survival and cyotokine expression independent of treatment in comparison to all other knock-out or over-
expression experiments. The model has thus generated predictions with respect to responsiveness of T cells to 
mono- or dual-costimulation given knowledge of the activity of these pathways. For example, in cells with inhi-
bition of the ERK pathway, mono- and dual-costimulation are predicted to increase cytokine expression, but 
only dual-costimulation would significantly impact survival. On the other hand, cells with overactive PKB can 
be expected to survive longer independent of treatment, but be responsive to treatment with respect to cytokine 
Figure 4. Steady-state (a) Survival (S) and (b) Cytokine release (C) in simulated cells that have been 
costimulated with 4-1BB (I) and/or OX40 (Ox) under knock-out or overexpression conditions of ERK, 
PKB, JNK, or Nk. If the model species name differs from the biological name, the model species name is in 
parentheses.
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secretion. These predictions can help to guide experimental investigation towards a more comprehensive under-
standing of the influence of CD8 T cell phenotype to treatment response.
Discussion
In this work, we have developed a stochastic multistate discrete model of CD8 T cell costimulatory receptor dual 
costimulation by agonists 4-1BB and OX40. Using in silico simulations of agonist stimulation, we have shown 
that the model can capture the experimental results observed for both mono- and dual-costimulation. We have 
further shown that the model can identify the NF-κB pathway as the strongest contributor to the dual costimu-
lation effect, which was shown experimentally by Lee et al.42. Finally, we have simulated response of the model to 
knock-out or overexpression conditions for key pathways in order to generate predictions of the responsiveness 
of T cells with heterogeneous phenotypes to both mono- and dual-costimulation.
We note that while there several methods to quantify synergy47, none of them account for discrete mod-
els. While we are unable to quantify the extent of synergy that may occur with dual costimulation over mono 
costimulation, we do observe that the model replicates the qualitative increase in response when the two drugs 
are given in combination in comparison to just one drug. Moreover, we surmise that superadditivity is present in 
the response, at least in survival, based on the following argument: we observe that in ERK knock-out conditions 
(which boost BIM activity), there is no longer any increase in survival in mono costimulation conditions, and a 
Figure 5. Multistate rule specification for the model of dual costimulation of CD8 T cells. Transition tables are 
displayed for each modeled species.
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maximal increase in survival in dual costimulation conditions (Fig. 4(a)), which strongly suggests synergy (by 
any measure of it), and shows that dual costimulation allows the system to overcome the knock-out-induced 
increase in BIM-mediated pro-apoptotic activity. Therefore, we can conclude that even in wild-type conditions, 
where ERK activity may be increased depending on the costimulation provided, and therefore survival may be 
boosted further by the consequent lowering of BIM activity, there is already synergy in survival response to dual 
costimulation even in presence of BIM activity. While we do not see similar results with the cytokine expression, 
we can still conclude that there is a maximization of this response in dual costimulation vs. mono costimulation 
- and the extent to which it occurs (superadditive or additive) will require a more fine-grained model to assess.
We focus on the survival and cytokine pathways for CD8 T cell costimulation, because the available data is the 
most clear on these two phenotypic outcomes for both mono- and dual-costimulation of these cells. For example, 
Lee et al.13 observed that increase in dual costimulation-mediated T cell number was not due to cell cycle entry, 
indicating that the survival pathways are more critical to the observed changes in dual costimulation-mediated 
cell number than an increase in proliferation. Importantly, the model can not only capture the strong response 
of CD8 T cells to dual costimulation that was observed by Lee et al.13, but it can also be used to understand the 
molecular underpinnings of the supereffector response.
Of the central pathways downstream of the TRAF proteins involved in the dual costimulation response, 
NF-κB was found to be a critical player (Fig. 3). It is conceivable that NF-κB may play a more central role in 
immunotherapy synergy if a broader range of targets is considered. Indeed, the NF-κB pathway has been found 
to be critical for T-cell elimination of tumors in vivo48, and CTLA-4 has been shown to inhibit TCR-mediated 
NF-κB49. It thus may be of interest to understand and model how to optimize NF-κB stimulation via a combina-
tion of agonists (e.g. OX40 and 4-1BB) and antagonists (e.g. CTLA-4 and PD-1), and how the responsivity of the 
T cells to these therapies may change under conditions of tumor-mediated immunoediting, as tumors are known 
to secrete factors that may inhibit TCR-mediated NF-κB activation (and, potentially, OX40- and 4-1BB-mediated 
NF-κB activation). More generally, incorporation of CTLA-4 and PD-1 pathways into the model may be of inter-
ested for future work in order to better understand whether the activation of these checkpoint inhibitory path-
ways in T cells may interfere with respect to mono- or dual-costimulation effectiveness of OX40 and/or 4-1BB 
agonists.
There were a number of biological details that we chose to omit from the model, but may be included in the 
future. For example, our assumption of optimal TCR triggering is based on the experimental studies that we 
have used to build our model. A more graded response to mono- and dual-costimulation under conditions of 
sub-optimal triggering would be of value to model with appropriate experimental evidence, since this is likely 
what occurs in an in vivo setting. Similarly, graded mono- and dual-costimulation (in comparison to maximal, as 
we model) may be also considered for future modeling efforts with appropriate experimental validation, since it 
is of interest to consider how dosage of one or both agonists impacts the costimulation response. Further, it has 
Figure 6. Example of an instantiation of the update function for PKB. The colors of the boxes indicate their 
activity level (high, medium, or low), and the time is indicated on the lower right-hand corner of each variable 
box. The value for PKB at time = t + 1 can either be medium (if the update rule is enacted, highlighted by the 
green coloring of the time and update probability), or low (if the update rule is not enacted, highlighted by the 
red coloring of time and probability).
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been shown that NF-κB is a transcription factor for TRAF1 and TRAF250,51. We chose not to include this feed-
back since its strength and time-course have not been evaluated in T cells, thus we do not have information on 
what role it plays in this system. Similarly, increase in cytokine production can theoretically result in autocrine 
feedback loops (e.g. binding of TNFα to the TNFR) that could further boost activation of the molecular actors in 
our model, since TNFR signals through TRAF2 (such an autocrine feedback loop was recently shown to exist for 
Treg cells52). Since we do not have information about the activity of such feedback loops for our no-costimulation 
model, and if such loops would be promoted further upon mono- or dual costimulation, we do not include 
this hypothetical feedback loop in our model. Nevertheless, even without incorporation of these factors, we still 
observe a maximal intracellular response to dual costimulation in the model, indicating that these factors may not 
be critical for the experimentally observed dual costimulation effect.
The CD8 T cell model of dual costimulation signaling may be relevant to therapeutic scenarios such as CAR 
T cell therapy where chimeric antigen receptors can be engineered to contain signaling motifs derived from 
different costimulatory receptors53. In this case, understanding of the mechanisms by which dual costimulation 
optimally boosts T cell response can be used to better understand how, and under what intracellular conditions, 
a CAR designed with OX40 and 4-1BB signaling motifs would optimally promote expansion of supereffector 
T cells. Moreover, OX40 and 4-1BB are expressed on activated CD4 (T helper) and constitutively on FoxP3+ 
CD25+ CD4+ (Treg) cells54–57. The intercellular interactions between these and CD8 cells in a dual costimulation 
environment will impact CD8 activity, as well as more broadly alter the immunogeneicity of tumors in which 
these cells act. Therefore, development of a multi-scale model encompassing both intracellular signaling cascades 
activated by dual costimulation and intercellular interactions potentiated in this environment will generate a 
mechanistic framework from which to disentangle the effect of the intra- vs. inter-cellular interactions on dual 
costimulation-mediated T cell costimulation, as well as to simulate conditions under which the population will 
be most (or, least) responsive to dual costimulation in order to create predictive models of dual costimulation effi-
cacy. The intracellular dual costimulation CD8 T cell model presented here provides a first step in this direction.
Methods
The model was simulated in Matlab R2017A using an asynchronous stochastic update scheme. Initial conditions 
were set to baseline physiological levels before 4-1BB (I) and/or OX40 (Ox)-mediated changes in molecular spe-
cies activity. Notably, initial conditions (aside from I and Ox) did not impact the steady states. We provide an 
overview of the modeling scheme here, and provide more detailed modeling and simulation methods, including 
methods for the modification of the model for knock-out and overexpression experiments, in the Supplementary 
Material.
System variables, which include the downstream molecular species of 4-1BB and OX40, can take on three 
levels of activity: low, medium, or high. These levels are represented with the values of 0, 1, and 2, respectively. A 
state vector at time t gives the values of all model species at t. The state vector is updated in discrete time using the 
transition tables in Fig. 5 for each species. At each update step, the molecular species are updated asynchronously 
in order to better reflect noisy biological processes. In the same vein, a species is updated with probability p < 1, 
since not all possible interactions are assumed to occur at each time step. Finally, each species is only allowed to 
jump a maximum of one level at any time step, allowing for a continuous transition between levels for the system 
during the course of the simulation. The system attains a steady state when the state vector remains constant 
during incremental time steps.
We consider an expository example: the transition table for PKB (Fig. 5e) shows that Tr2 and Ox both contrib-
ute to PKB activation. Let us assume that PKB at the current time, t, is high, Tr2 is low, and Ox is medium (Fig. 6). 
According to the transition table, PKB should transition to low activity at the next time step. Due to the continuity 
constraint, PKB will drop to a medium level, but only if the update rule is enacted, since there is some probability, 
(1 − p), that PKB will not update and remain at its original high level.
We shall now discuss the derivation of each of the rules in the multistate rule-specification transition tables 
depicted in Fig. 5.
The TRAF proteins. Both OX40 and 4-1BB bind and activate TRAF229,58–60, while OX40 has also been shown 
to activate TRAF5 and TRAF329,58, and 4-1BB, TRAF158. It has been shown that TRAF3 acts to negatively regu-
late TRAF2-mediated downstream-signaling by competing with TRAF2 for binding with OX4061. To reduce the 
overall number of variables in the model, we do not model TRAF3 directly, but we make the effect of 4-1BB on 
TRAF2 activation to be stronger than that of OX40 to account for the added action of TRAF3 on OX40-mediated 
TRAF2 activation. Finally, as it has been found that TRAF1 is involved in the promotion of TRAF2 activity62, we 
incorporate this effect into the function for TRAF2. We construct the update rules for the species representing 
TRAF2 (Tr2) as follows. We first create a stimT variable that combines the effects of 4-1BB (I) and OX40 (Ox), with 
I having the stronger effect on the value of stimT. We set the temporary value of Tr2 == stimT. Next, TRAF1 (Tr1) 
can boost (or, mitigate if it is = 0) stimT to generate the final update value of Tr2 (Fig. 5b). The activity of Tr1 and 
TRAF5 (Tr5) are set to be proportional to I and Ox activity, respectively (Fig. 5a,c).
NF-κB. The NF-κB pathway, which controls cell survival and inflammatory pathways, is activated by both 
OX40 and 4-1BB in a TRAF-dependent manner58,59. TRAF2-mediated activation of the canonical NF-κB path-
ways has been well characterized59,63, but a dominant-negative mutant of TRAF5 has also been shown to reduce 
OX40-mediated NF-κB activation29. Since the evidence for TRAF2-dependent activation of NF-κB is stronger 
than for TRAF5, we model Tr2 to have a stronger effect on NF-κB (Nk) activation than Tr5 (Fig. 5d).
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PKB, Bim, and JNK. Protein Kinase B (PKB) (also known as AKT) is a Serine and Threonine Kinase that is 
activated by the lipid kinase PI3K and is involved in the regulation of many central cellular processes, including 
cell survival64. It has been shown that OX40-mediated survival of activated CD4 T cells is dependent upon PKB 
activation17, which is dependent upon TRAF2 activity65. Nevertheless, 4-1BB-induced survival of CD8 T cells 
has been shown to be independent of the PI3k/PKB cascade66. While the former experiments were conducted in 
CD4 T cells, and the latter in CD8, until further evidence is presented, we assume that downstream signaling of 
activated OX40 and 4-1BB is mediated by the same molecular species. We thus model PKB activation as a process 
mediated by Ox and Tr2 (Fig. 5e).
The pro-survival effect of 4-1BB signaling is partially dependent on TRAF1 activity, which inhibits the 
pro-apoptotic BCL-2 family member Bim in an ERK-dependent pathway67. Additionally, in an ERK-independent 
pathway, PKB acts as an inhibitor of Bim via inactivation by phosphorylation of members of the FoxO transcrip-
tion factor family, which promote Bim transcriptional upregulation68,69. The effect of Bim inhibitory inputs may 
be modulated by direct activation of Bim by c-Jun N-terminal Kinase (JNK) via phosphorylation, thereby leading 
to its release from dynein and myosin V motor complexes which sequester it from its pro-apoptotic activities70. 
JNK, a member of the mitogen-activated protein kinase (MAPK) family, is activated via a MAPK phosphoryla-
tion cascade71 that has been shown to be initiated by TRAF2 (via activation of higher level MAP4K AKT1, as well 
as other upstream MAPKs)72–74 (reviewed in16). NF-κB has been shown to be an inhibitor of JNK activation in a 
manner that is independent of a downstream effect of caspase activation (which occurs upon NF-κB inhibition) 
and is transcriptional in nature75–78. Hence, we take activity of Bim inhibitors (inhB) to be equal to the max(Tr1, 
PKB) and model Bim activation as a balance between inhB and JNK, and JNK activity as a balance between acti-
vator Tr2 and inhibitor Nk (Fig. 5f,g).
Survival and cytokine production. Apoptosis, or programmed cell death, can be initiated via several 
pathways that converge upon the activation of the caspase family of proteins, which enact the apoptotic process of 
cellular component degradation79. One pathway, termed the ‘intrinsic pathway’, occurs via Bcl2-family-mediated 
permeabilization of the mitochonrial outer membrane, which is a signal for initiation of the caspase cascade. 
The Bcl2 family contains both pro- and anti-apoptotic members, and it is the balance of these different species 
which determines where apoptosis is initiated or not via this pathway80,81. We have already discussed how 4-1BB 
signaling can lower the activity of Bim, a pro-apoptotic member of this family30. Activation of NF-κB results in 
the enhanced expression of pro-survival members of the Bcl2 family, including A1/Bfl1 and Bcl-xL, as well as 
activation of other arms of the anti-apoptotic cellular machinery16,82–84. Additionally, apoptosis signaling path-
ways are activated by PKB64, and inhibited by JNK85 (independent of their respective action on Bim, discussed 
earlier). Therefore, survival is modeled as a balance between the levels of survival-promoting and inhibiting 
species (Fig. 5h). NF-κB regulates production of cytokines by activated T cells, including IL-2, IL-6, IFNγ, and 
TNFα84,86,87. JNK has also been implicated in the production of IL-2 during T cell activation, but to differing 
extents depending on the study88. Therefore, we model cytokine production as a function of NF-κB and JNK, with 
NF-κB having the stronger positive effect (Fig. 5i).
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